SYDNEY, Sept. 9, 2020 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Paediatric Disease Designation (RPDD) to ⁶⁴Cu-SARTATE™, a diagnostic for the clinical management of...